

Croup Clinical Pathway

Center for Urgent Care & Emergency Department Clinical Excellence



- Age 6 months to 6 vears
- Signs & Symptoms of croup

Exclusion Criteria:

- Toxic appearance
- Symptoms suggestive of an alternative diagnosis
- Known upper airway abnormality
- Hypotonia or neuromuscular disorder
- Chronic lung disease (BPD, CF, pulmonary artery hypertension)
- Recent airway instrumentation
- Congenital or acquired heart disease
- Foreign body aspiration or ingestion

Discharge

home

Hypoxia

distress

intubation

Stridor at rest



status changes

Off Pathway



CPP-ED-UC Croup Clinical Pathway Published: 2/1/2023; Revised: 2/1/2023

PICU

Croup is a common respiratory illness of the larynx, trachea, and bronchi that leads to **inspiratory** stridor and a barking cough. It is usually caused by a virus. Croup is primarily a clinical diagnosis, with typical findings of abrupt onset of a barking cough, inspiratory stridor, hoarseness, and sometimes dyspnea and fever. Biphasic stridor, when present, may represent more severe disease.

Differential Diagnosis

Signs and symptoms suggestive of an alternative diagnosis:

- Age < 6 months or > 6 years
- Expiratory wheeze
- Drooling or difficulty swallowing
- Prolonged or recurrent stridor
- Recurrent croup (2nd episode within 30 days or > 3 episodes in the last 12 months)
- Toxic appearance
- Poor response to treatment
- Asymmetry of respiratory exam
- Non-elective intubation in the past 6 months or history of prolonged intubation

Alternative Diagnoses:

Bacterial tracheitis

• Signs/symptoms of croup that have markedly worsened, toxic appearing, poor response to racemic epinephrine

Epiglottitis

 Incomplete immunizations, absence of barky cough and presence of anxiety that is out of proportion to degree of respiratory distress, fever, toxic appearing, drooling, swelling of epiglottis "thumb sign" on lateral radiograph

Foreign body aspiration

• History of choking in previously healthy child

Large airway lesions, hemangioma, neoplasm

- Chronic course and absence of fever **Known upper airway abnormality**
- Vocal cord paralysis, subglottic stenosis, tracheomalacia, history of vascular ring or TEF
 Deep neck space abscesses (peritonsillar abscess, retropharyngeal abscess, parapharyngeal abscess)
- Fever, drooling, neck stiffness, lymphadenopathy and varying degrees of toxicity, barky cough absent

Thermal injury/smoke inhalation Asthma

• Lower airway sounds rather than stridor

Anaphylaxis or Angioedema

Rapid onset without antecedent URI symptoms or fever



Recommended Treatments

Dexamethasone (0.6 mg/kg, max 16 mg) PO, IV, IM should be administered by the least invasive route possible.

Racemic epinephrine (0.5 mL of a 2.25% solution diluted to 3 mL total volume with normal saline) should be given to all patients with moderate-severe croup.

Onset: 10-30 minutes Can be repeated after 20 minutes if symptoms persist Duration: 1-2 hours

Heliox is a mixture of helium (70-80%) and oxygen (20-30%) that promotes laminar flow of air rather than turbulent flow. When administered via a non-rebreather mask heliox can decrease the work of breathing in children with severe symptoms. Use of heliox is limited in children with hypoxia because of the low fractional concentration of oxygen in the gas mixture.

Consider ENT consultation / referral:

- Recurrent croup (2nd episode within 30 days or > 3 episodes in the last 12 months)
- Atypical croup (crescendo onset, age < 6 months or > 6 years)
- Recent non-elective intubation
- History of prolonged intubation

Treatments Not Routinely Recommended

Radiographs: not indicated in the vast majority of children with croup. Imaging is indicated in the following circumstances:

- Atypical course and diagnosis is not clear
- Severe symptoms without adequate response to therapeutic interventions
- Concern for inhaled foreign body
- Recurrent episodes of croup

Viral testing: not routinely necessary but may be useful when making decisions about isolation

Cool mist: lack of proven benefit but may be used if comforting to the child

Repeat dexamethasone: not routinely recommended unless symptoms persist

References

- Bjornson C, Johnson DW, McMillan A, et al. Cochrane Review: Nebulized Epinephrine for Croup in Children. *Evidence-Based Child Health: A Cochrane Review Journal*. 2012;7(4):1311-54.
- Bjornson CL, Johnson DW. Croup-treatment update. *Pediatr Emerg Care*. 2005;21(12):863-70; quiz 871-3. doi:10.1097/01.pec.0000190225.04986.e0.
- Cherry JD. Croup. N Engl J Med. 2008;358(4):384-91.
- Cooper T, Cohen D, Choi S, et al. Atypical croup: association with airway lesions, atopy, and esophagitis. *Otolaryngol Head Neck Surg.* 2012;147(2):209-14. doi:10.1177/0194599812447758.
- Gates A, Cummings C, Sinha I, et al. Glucocorticoids for croup in children. *Cochrane Database Syst Rev.* 2018;8.
- Johnson DW. Croup. BMJ Clin Evid. 2014;2014:1-11.
- Moraa I, Koonin S, Sinha I, et al. Heliox for croup in children. Cochrane Database Syst Rev. 2021;8.
- Parker CM, Cooper MN. Prednisolone versus dexamethasone for croup: a randomized controlled trial. Pediatrics. 2019;144(3).
- Scolnik D, MacFarlane M, Koren G, et al. Controlled delivery of high vs low humidity vs mist therapy for croup in emergency departments: a randomized controlled trial. *JAMA*. 2006;295(11):1274-80. doi:10.1001/jama.295.11.1274.
- Smith DK, Geller S, Dreyer R, et al. Croup: diagnosis and management. *Am Fam Physician*. 2018;97(9):575-80.
- Udoh I, Torkelson D, Raith M, et al. Retrospective evaluation of return rates in pediatric patients treated with inhaled racemic epinephrine for croup. *WMJ*. 2022;121(1):26-29.
- Weber JE, Kearns GL, Fuhrman B, et al. A randomized comparison of helium-oxygen mixture (heliox) and racemic epinephrine for the treatment of moderate to severe croup. *Pediatrics*. 2001;107(6). doi:10.1542/peds.107.6.e96.
- Westley CR, McMurray J, Smith B, et al. Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study. *Am J Dis Child*. 1978;132(5):484-7.
- Yang WC, Chang YJ, Chen YJ, et al. Westley score and clinical factors in predicting the outcome of croup in the pediatric emergency department. *Pediatr Pulmonol.* 2017;52(10):1329-34.
- Bagwell T, Hollingsworth A, et al. Management of croup in the emergency department: the role of multidose nebulized epinephrine. *Pediatr Emerg Care*. 2020;35.
- Udoh I, Heegeman D, Ravi S. Retrospective evaluation of return rates in pediatric patients treated with inhaled racemic epinephrine for croup. *WMJ*. 2022;121:26-29.
- Croup severity score adapted from:
 - Fitzgerald DA, Kilham HA. Croup: assessment and evidence-based management. *Med J Aust.* 2003;179(7):372-7. doi:10.5694/j.1326-5377.2003.tb05597.x.
 - Clare E, Martin M, et al. Johns Hopkins All Children's Hospital. Croup Clinical Pathway, Dec 13, 2021. Accessed from: https://www.hopkinsmedicine.org/-/media/files/allchildrens/clinical-pathways/croup-clinical-pathway-12_13_2021.pdf
 - Tyler A, Gardner H, Cripe J, et al. Children's Hospital Colorado. Croup Clinical Pathway, Aug 11, 2011. Updated Oct 7, 2021. Accessed from: https://www.childrenscolorado.org/globalassets/ healthcare-professionals/clinical-pathways/croup.pdf

Team & Process

Content Development Team:

Leaders:

Pharmacy:

Members:

Urgent Care:

Emergency Medicine:

Emergency Medicine:

Respiratory Care:

Otolaryngology:

Clinical Pathways Program:

Medical Director – Emergency Medicine: Berkeley Bennett, MD, MS Medical Director - Clinical Informatics & Emergency Medicine: Laura Rust, MD, MPH Physician Informatics: Berkeley Bennett, MD, MS Kathy Nuss, MD Business & Development Manager: Rekha Voruganti, MBOE, LSSBB Program Coordinators: Tahje Brown, MBA Tara Dinh, BS **Clinical Pathway Approved:** Medical Director - Associate Chief Quality Officer, Center for Karla Hauersperger, MD Clinical Excellence: Traci Downs-Bouchard, MD Ryan Bode, MD, MBOE Origination Date: February, 2023 Next Revision Date: February, 2026

Amy Manning, MD Charles Elmaraghy, MD

Punam Shingala, MRT

Sarah Chen, MD

Betsy Schmerler, MD

Kim Jones, PharmD

Luciana Berg, MD

Kathryn Nuss, MD

Kelli Mavromatis, RN Laura Rust, MD, MPH

Clinical Pathway Development

This clinical pathway was developed using the process described in the NCH Clinical Pathway Development Manual Version 6, 2022. Clinical Pathways at Nationwide Children's Hospital (NCH) are standards which provide general guidance to clinicians. Patient choice, clinician judgment, and other relevant factors in diagnosing and treating patients remain central to the selection of diagnostic tests and therapy. The ordering provider assumes all risks associates with care decisions. NCH assumes no responsibility for any adverse consequences, errors, or omissions that may arise from the use or reliance on these guidelines. NCH's clinical pathways are reviewed periodically for consistency with new evidence; however, new developments may not be represented, and NCH makes no guarantees, representations, or warranties with respect to the information provided in this clinical pathway.

Copyright © 2023. Nationwide Children's Hospital. All rights reserved. No part of this document may be reproduced, displayed, modified, or distributed in any form without the express written permission of Nationwide Children's Hospital.

For more information about our pathways and program please contact: ClinicalPathways@NationwideChildrens.org

Algorithm

Goals & Metrics

Goal

To appropriately diagnose and effectively treat patients with croup.

Population

Inclusion:

- Age: \geq 6 months to \leq 6 years.
- Diagnoses:

Patients presenting to the ED/UC with a diagnosis of croup (can use a SNOMED concept for this) or who received a racemic epinephrine treatment.

- Care Settings:
 - ED

UC

Exclusions:

- Congenital heart disease
- BPD
- Cystic fibrosis

Metrics:

Process measures:

ED/UC Order Panel & SmartSet utilization

Outcome measures:

ED:

- ED length of stay
- Time from racemic epinephrine administration to discharge disposition.
- Admission rate
- Percent of non-ICU admitted patients who do not receive supplemental oxygen AND do not receive additional racemic epinephrine treatments.

UC:

- UC length of stay
- Time from racemic epinephrine administration to discharge disposition.
- Transfer rate

Balancing measure:

72hr ED/UC bounce back rate

